Dipanjan Bhattacharyya

Dr. Dipanjan Bhattacharyya


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2018 in Metabolites
Verified
Journal Article
Open access
PDF file
YKYeganeh Khaniani
Yeganeh Khaniani
MLMatthias Lipfert
Matthias Lipfert
DBDipanjan Bhattacharyya
Dipanjan Bhattacharyya
RPRolando Perez Pineiro
Rolando Perez Pineiro
JZJiamin Zheng
Jiamin Zheng
David Scott WishartDavid Scott Wishart
David Scott Wishart
An improved method to synthesize the highly abundant and biomedically important urinary metabolite 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA) is reported. The modified protocol is based on an indium-mediated sonochemical Reformatsky reaction. The synthesis is a simple two-step route as opposed to a complex four-step route previously reported in the literature that requires specialized equipment, flammable materials, and high-pressure reaction vessels. The described procedure also provides an expedient route to prepare a 13C isotopically labeled HPHPA that can be used as a standard for quantitative LC-MS analysis. This report also illustrates how the synthesized metabolite standard was used to detect and accurately quantify its presence in human urine samples using both NMR and LC-MS techniques.

2 September 2026 in Biosensors
Verified
Journal Article
Open access
PDF file
Prashanthi KovurPrashanthi Kovur
Prashanthi Kovur
SMScott Mackay
Scott Mackay
SBSong Tian Bai
Song Tian Bai
JCJames Daniel Joseph Cook
James Daniel Joseph Cook
CTClaudia Torres-Calzada
Claudia Torres-Calzada
David Scott WishartDavid Scott Wishart
David Scott Wishart
Early detection of colorectal cancer (CRC) is challenging in low-resource settings because access to colonoscopy and centralized laboratory testing is limited. Urine-based metabolite biomarkers offer a non-invasive alternative for CRC triage, but translating a laboratory assay into a point-of-care (PoC) system requires standardized fluid handling, operator-independent timing, field-compatible reagents, and quantitative calibration. Here, we present a low-cost, semi-automated PoC platform integrating a validated, sequential, three-metabolite CRC-biomarker assay with robotic fluid handling, a motorized chromatographic module, an optical reader, Bluetooth electronics, and tablet-guided control. The platform measures urinary diacetylspermine and hippuric acid, with creatinine serving as a normalization reference, and reports absolute quantitative concentrations. Automated dilution, tube positioning, timed incubation, controlled column elution, and software-guided transfer reduce operator-dependent variation. Using pooled urine samples spiked at clinically relevant concentrations, the creatinine assay showed a strong quadratic response (0–50 mM, R2 = 0.998), as did the diacetylspermine assay (0–4 μM, R2 = 0.979), while the hippuric acid assay showed a linear response of R2 = 0.989. The RGB sensor tracked the concentration-dependent trend observed with a laboratory microplate reader (R2 = 0.968–0.999). Reagents reformulated as lyophilized or pre-weighed, vacuum-sealed kits withstood accelerated heat and humidity (45 °C/70% RH) testing and international shipping to the pilot site very well. At approximately USD 490 for the complete instrument (including tablet) and roughly USD 7.65 in consumables per screening test, the platform offers a practical, quantitative, and portable route for decentralized CRC screening.